{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:25:46Z","timestamp":1788218746422,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjmed.2022.02.005","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T09:21:03Z","timestamp":1645953663000},"page":"S9-S12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S1","title":["Management of Cardiac Symptoms in Amyloidosis"],"prefix":"10.1016","volume":"135","author":[{"given":"Phillip","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.amjmed.2022.02.005_bib0001","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"22","key":"10.1016\/j.amjmed.2022.02.005_bib0002","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjmed.2022.02.005_bib0003","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1161\/CIRCULATIONAHA.111.069195","article-title":"Cardiac amyloidosis","volume":"126","author":"Quarta","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjmed.2022.02.005_bib0004","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.amjmed.2022.02.005_bib0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2022.02.005_bib0006","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"8","key":"10.1016\/j.amjmed.2022.02.005_bib0007","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jcmg.2021.01.016","article-title":"Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis","volume":"14","author":"Huntjens","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.amjmed.2022.02.005_bib0008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.amjmed.2022.02.005_bib0009","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"issue":"21","key":"10.1016\/j.amjmed.2022.02.005_bib0010","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjmed.2022.02.005_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"issue":"7","key":"10.1016\/j.amjmed.2022.02.005_bib0012","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electr"},{"issue":"8","key":"10.1016\/j.amjmed.2022.02.005_bib0013","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/europace\/euaa094","article-title":"Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator","volume":"22","author":"Kim","year":"2020","journal-title":"Europace"},{"issue":"41","key":"10.1016\/j.amjmed.2022.02.005_bib0014","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.amjmed.2022.02.005_bib0015","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.amjmed.2022.02.005_bib0016","first-page":"e333","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.amjmed.2022.02.005_bib0017","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"issue":"11","key":"10.1016\/j.amjmed.2022.02.005_bib0018","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"14","key":"10.1016\/j.amjmed.2022.02.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017335","article-title":"Cardiac resynchronization therapy for transthyretin cardiac amyloidosis","volume":"9","author":"Donnellan","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2022.02.005_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10286-019-00623-x","article-title":"Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management","volume":"29","author":"Palma","year":"2019","journal-title":"Clin Auton Res"},{"issue":"10","key":"10.1016\/j.amjmed.2022.02.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006848","article-title":"Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension","volume":"6","author":"Grijalva","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.amjmed.2022.02.005_bib0022","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.02.005_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322001103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322001103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:25:53Z","timestamp":1757582753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":23,"alternative-id":["S0002934322001103"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.02.005","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Cardiac Symptoms in Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}